Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

Annals of Oncology

Volumn 26, Issue 9, 2015, Pages 1904-1910

  Diéras, Véronique ^a   Campone, M ^b   Yardley, D A ^c   Romieu, G ^b   Valero, V ^d   Isakoff, S J ^e   Koeppen, H ^f   Wilson, T R ^f   Xiao, Y ^f   Shames, D S ^f   Mocci, S ^f   Chen, M ^g   Schmid, P ^h  

^a INSTITUT CURIE   (France)

^b CENTRE VAL D AURELLE   (France)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f GENENTECH INC   (United States)

^g Roche Pharma Development Center in China   (China)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bevacizumab; MET; Onartuzumab; Paclitaxel; Phase II; Triple negative breast cancer

Indexed keywords

BEVACIZUMAB; ONARTUZUMAB; PACLITAXEL; PLACEBO; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TRIPLE NEGATIVE BREAST CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PLACEBOS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84941643538     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv263     Document Type: Article

References (20)

1. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
2. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
3. Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33: 13-21.
4. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
5. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172.
6. Miles DW, Diéras V, Cortés J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24: 2773-2780.
7. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-848.
8. Charafe-Jauffret E, Ginestier C, Monville F et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006; 25: 2273-2284.
9. Graveel CR, DeGroot JD, Su Y et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009; 106: 12909-12914.
10. Garcia S, Dalès JP, Charafe-Jauffret E et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007; 38: 830-841.
11. Zagouri F, Bago-Horvath Z, Rössler F et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013; 108: 1100-1105.
12. Ho-Yen CM, Green AR, Rakha EA et al. C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? Cancer 2014; 120: 163-171.
13. Merchant M, Zheng Z, Romero M et al. One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking anti-c-Met monovalent antibody that inhibits HGFdependent activity in vitro and demonstrates anti-tumor efficacy in vivo. In Presented at the American Association of Cancer Research Annual Meeting. Los Angeles, CA, 14-17 April 2007. Abstract LB-372.
14. Koeppen H, Januario T, Filvaroff E et al. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. In Presented at the Annual Meeting of the United States and Canadian Academy of Pathology. Vancouver, BC, Canada, 17-23 March 2012. Abstract 2001.
15. Spigel DR, Ervin TJ, Ramlau RA et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 4105-4114.
16. Mazières J, Brugger W, Cappuzzo F et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 2013; 82: 231-237.
17. Schleifman EB, Desai R, Spoerke JM et al. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS ONE 2014; 9: e88401.
18. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
19. Xin Y, Jin D, Eppler S et al. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol 2013; 53: 1103-1111.
20. Lu JF, Bruno R, Eppler S et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-786.